About: Orphan drugs
Special ReportPromoted content

Europe at the crossroad of Rare Diseases innovation: lessons from the past and future outlooks
In shaping the future of rare diseases policies all stakeholders should cooperate to create an environment that actively supports research and clinical development of orphan medicinal products (OMPs). This entails building synergies all across the innovation ecosystem to address the...Special ReportPromoted content

The complexity of R&D for orphan medicines
There are multiple challenges inherent to drug development for rare diseases, all consequences of the small number of patients. For most of these diseases, the body of pre-existing knowledge is extremely limited with a lack of crucial information such as...Special ReportPromoted content
